Cost minimization analysis of two treatment regimens for low‐risk rhabdomyosarcoma in children: A report from the Children's Oncology Group

Recent Children's Oncology Group trials for low‐risk rhabdomyosarcoma attempted to reduce therapy while maintaining excellent outcomes. D9602 delivered 45 weeks of outpatient vincristine and dactinomycin (VA) for patients in Subgroup A. ARST0331 reduced the duration of therapy to 22 weeks but added four doses of cyclophosphamide to VA for patients in Subset 1. Failure‐free survival was similar. We undertook a cost minimization comparison to help guide future decision‐making.

[1]  B. Stevens,et al.  A mixed method approach to describe the out‐of‐pocket expenses incurred by families of children with cancer , 2013, Pediatric blood & cancer.

[2]  B. Stevens,et al.  Determining the Costs of Families’ Support Networks Following a Child’s Cancer Diagnosis , 2013, Cancer nursing.

[3]  P. Katz,et al.  Time costs of fertility care: the hidden hardship of building a family. , 2010, Fertility and sterility.

[4]  D. Hawkins,et al.  Rhabdomyosarcoma: Review of the Children's Oncology Group (COG) soft‐tissue Sarcoma committee experience and rationale for current COG studies , 2012, Pediatric blood & cancer.

[5]  Thomas J. Smith,et al.  American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  James R. Anderson,et al.  Rhabdomyosarcoma in infants younger than 1 year , 2011, Cancer.

[7]  J. Meza,et al.  Shorter duration therapy that includes vincristine (V), dactinomycin (A), and lower doses of cyclophosphamide (C) with or without radiation therapy for patients with newly diagnosed low-risk embryonal rhabdomyosarcoma (ERMS): A report from the Children's Oncology Group (COG). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  James R. Anderson,et al.  Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's O , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  N. Adler,et al.  Costs of infertility treatment: results from an 18-month prospective cohort study. , 2011, Fertility and sterility.

[10]  J. Beyene,et al.  Cost-effectiveness of Outpatient Management for Febrile Neutropenia in Children With Cancer , 2011, Pediatrics.

[11]  P. Babyn,et al.  Effect of anesthesia and sedation on pediatric MR imaging patient flow. , 2010, Radiology.

[12]  S. Spunt,et al.  Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. McBride,et al.  Impact of childhood cancer on parental employment and sources of income: A Canadian pilot study , 2008, Pediatric blood & cancer.

[14]  A. Ferrari,et al.  Full‐dose ifosfamide can be safely administered to outpatients , 2008, Pediatric blood & cancer.

[15]  James R. Anderson,et al.  Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Stevens.  Treatment for childhood rhabdomyosarcoma: the cost of cure. , 2005, The Lancet. Oncology.

[17]  S. Bartel,et al.  Variation in administration of cyclophosphamide and mesna in the treatment of childhood malignancies. , 2001, Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses.

[18]  A. Pappo,et al.  Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: A Pediatric Oncology Group Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  N. West,et al.  Prevention and Treatment of Hemorrhagic Cystitis , 1997, Pharmacotherapy.

[20]  H. B. Marsden,et al.  Results of the United Kingdom Children's Cancer Study Group first Wilms' Tumor Study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.